The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Merck; Novartis; Roche
Consulting or Advisory Role - Novartis; Roche
Travel, Accommodations, Expenses - Merck; Swedish Orphan Biovitrum
Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification: Final results of EORTC 90101 CREATE.
 
Patrick Schoffski
No Relationships to Disclose
 
Agnieszka Wozniak
No Relationships to Disclose
 
Bernard Escudier
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Ipsen; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EUSA Pharma; Exelixis; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Piotr Rutkowski
No Relationships to Disclose
 
Alan Anthoney
Consulting or Advisory Role - Advanced Accelerator Applications; Novartis
 
Sebastian Bauer
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Pharmamar
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Lilly
Research Funding - Blueprint Medicines; Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Jozef Sufliarsky
No Relationships to Disclose
 
Carla M.L.- Van Herpen
No Relationships to Disclose
 
Lars Lindner
Stock and Other Ownership Interests - Thermosome
Consulting or Advisory Role - Eisai; Lilly; Novartis
Speakers' Bureau - Lilly
Research Funding - Sennewald GmbH
Travel, Accommodations, Expenses - Novartis; PharmaMar
 
Viktor Grünwald
Honoraria - Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Ipsen; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; PharmaMar; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Cerulean Pharma; Ipsen; Lilly; MSD Oncology; Novartis; Pfizer
Speakers' Bureau - Novartis; Pfizer
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer
 
Branko Zakotnik
No Relationships to Disclose
 
Evelyne Lerut
No Relationships to Disclose
 
Maria Debiec-Rychter
No Relationships to Disclose
 
Sandrine Marreaud
No Relationships to Disclose
 
Michela Lia
No Relationships to Disclose
 
Tiana Raveloarivahy
No Relationships to Disclose
 
Sandra Collette
No Relationships to Disclose
 
Laurence Albiges
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Ipsen (Inst); Novartis; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)